Linezolid (as part of regimens)
Treatment for Extensively drug-resistant tuberculosis
Typical Dosage: 300-600mg daily
Effectiveness
75%
Safety Score
35%
Clinical Trials
40
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
35
DangerousModerateSafe
Treatment Details
Dosage Range
300-600mg daily
Time to Effect
3-6 months
Treatment Duration
6-24 months
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$3,000
Side Effect Mgmt:$4,500
Total Annual:$9,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$35,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$13,571
Cost per Remission
$13,571
Comparison vs Less effective older XDR-TB regimens
Cost Difference
+$2,000/year
More expensive
QALY Difference
+0.60 QALYs
Better outcomes
Dominance
No dominance
Linezolid (as part of regimens) Outcomes
for Extensively drug-resistant tuberculosis
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov